Sunshine Biopharma Inc.
1.7600-0.08 (-4.35%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · SBFM · USD
Key Stats
Market Cap
8.63MP/E (TTM)
-Basic EPS (TTM)
-15.02Dividend Yield
0%Recent Filings
8-K
Auditor switch completed
Sunshine Biopharma Inc. dismissed Bush & Associates CPA LLC as its independent auditor and hired M&K CPAS, PLLC, effective September 24, 2025, with board and audit committee approval. No disagreements arose with Bush over accounting principles, disclosures, or audit scope in fiscal years 2023 and 2024, nor any reportable events. The switch happened cleanly. This routine change supports ongoing compliance amid Nasdaq listing demands.
10-Q
Q2 FY2025 results
Sunshine Biopharma posted Q2 revenue of $9.4M, up slightly y/y from $9.3M yet flat q/q, while gross profit jumped 45% y/y to $3.4M on a 63.6% margin—better than last year's 74.7% cost bite—thanks to cheaper finished goods sourcing. But operating loss widened to $2.1M y/y, driven by a $1.1M intangible impairment for uncommercializable licenses, plus higher consulting and salaries; net loss hit $1.8M, or $0.39/share on 4.5M shares, versus $0.49M last year on far fewer shares. YTD revenue rose 8.7% to $18.3M with gross profit up 31% to $6.2M, though net loss deepened to $2.95M from $1.78M amid those costs. Cash swelled to $10.3M on $3.9M financing inflows, including a $1.8M April offering and warrant exercises, with no debt but a pending $5.3M claim from a Nora Pharma exec termination. Free cash flow not disclosed in the 10-Q. Government pricing shifts in Canada's generic market pose ongoing risks.
8-K
Q1 revenues surge 18%
Sunshine Biopharma reported first-quarter 2025 revenues of $8.9 million, up 18% from $7.5 million last year, driven by strong generic drug sales. The company launched six new generics—two antibiotics, two for gastrointestinal disorders, and two for schizophrenia—while appointing Michel Roy as Chief Commercial Officer to bolster commercial efforts. Studies confirmed K1.1 mRNA's potential against liver cancer. Yet net loss narrowed to $1.2 million from $1.3 million. Forward-looking plans include 13 more launches, like NIOPEG® biosimilar, amid SEC-noted risks.
10-Q
Q1 FY2025 results
Sunshine Biopharma posted solid Q1 FY2025 revenue of $8.9M, up 18.0% y/y from $7.5M, fueled by new generic drug launches and broader marketing in Canada, while gross margin held steady at 30.7% versus 31.2% last year. Operating loss narrowed to $1.3M from $1.4M y/y, thanks to tighter controls on accounting and legal costs, though consulting and marketing ticked up; net loss eased to $1.2M or $0.44 per diluted share on 2.7M shares, aligning with the prior year's $1.3M or $2.00 on far fewer shares. Cash burn slowed, with operating cash use at $1.7M versus $3.2M y/y, leaving $8.1M in cash and no debt, bolstered by $355K from warrant exercises. Inventory grew to $11.9M amid pipeline expansion to 70 generics. Warrants remain a key liquidity lever. Yet regulatory shifts in Canadian drug pricing pose ongoing risks.
8-K
Sunshine Biopharma closes $2.46M offering
Sunshine Biopharma closed a $2.46 million registered direct offering on April 3, 2025, selling 928,404 common shares at $2.07 each and pre-funded warrants for 260,000 shares, netting $1.8 million after fees. This bolsters working capital amid oncology and antiviral pursuits, yet dilutes existing holders. Cash infusion fuels operations.
IPO
Employees
Sector
Industry
AMRX
Amneal Pharmaceuticals, Inc.
10.43+0.14
BIOE
Bio Essence Corp.
0.07+0.00
CBDL
CBD Life Sciences Inc.
0.00+0.00
CPHI
China Pharma Holdings, Inc.
1.78+0.02
CRLBF
Cresco Labs Inc.
1.20-0.00
FLGC
Flora Growth Corp.
10.35-1.30
HYPMY
Hypera SA
4.42-0.03
PHBI
Pharmagreen Biotech Inc.
0.00-0.00
PLSH
PANACEA LIFE SCIENCES HLDGS INC
0.07+0.00
UPC
Universe Pharmaceuticals Inc
4.82-0.29